论文部分内容阅读
目的回顾性分析脑恶性胶质瘤术后放化疗联合治疗临床疗效。方法对资料完整的126例脑恶性胶质瘤患者进行回顾性研究,分为单纯放疗组(64例)、给予术后单纯放疗和放化疗联合组(62例)、给予放疗后替尼泊苷联合司莫司汀化疗,对组间生存差异进行比较。结果成人恶性胶质瘤术后单纯放疗组1、3、5年生存率分别为64.06%、31.25%、15.63%;术后同步放化疗组1、3、5年生存率分别为80.65%、50%、30.65%。同步放化疗组生存率明显优于单纯放疗组(P<0.05)。结论脑恶性胶质瘤术后放化疗联合治疗有较好疗效,毒副反应可以耐受,值得临床推广。
Objective To retrospectively analyze the clinical effects of combined chemotherapy and radiotherapy for malignant glioma after operation. Methods A total of 126 patients with brain malignant glioma were retrospectively studied. The patients were divided into radiotherapy group (64 cases), radiotherapy combined with radiotherapy and chemotherapy group (62 cases), radiotherapy after teniposide Combination of temsirolimus chemotherapy, differences in survival between groups were compared. Results The 1, 3, 5-year survival rates of adult patients with malignant glioma after radiotherapy were 64.06%, 31.25% and 15.63% respectively. The 1, 3, 5-year survival rates of concurrent radiotherapy and chemotherapy group were 80.65%, 50 %, 30.65%. The survival rate of concurrent chemoradiotherapy group was significantly better than that of radiotherapy alone group (P <0.05). Conclusions The combination of radiotherapy and chemotherapy after brain glioblastoma has a good curative effect and the side effects can be tolerated. It is worthy of clinical promotion.